Medicenna Therapeutics (TSE:MDNA) has released an update.
Medicenna Therapeutics has revealed promising preclinical data for MDNA113, a pioneering anti-PD1-IL2 superkine therapy aimed at aggressive cancers, at the AACR 2024 meeting. The treatment targets IL-13Rα2, found in ‘cold’ tumors, and is designed to deliver dual immunotherapies directly to the tumor environment, enhancing efficacy while reducing systemic toxicity. The findings suggest MDNA113 could be more tolerable and effective in targeting over two million annual cancer cases, offering hope for better management of pancreatic, prostate, ovarian, breast, and brain cancers.
For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.
